Aida Pharmaceuticals (AIDA)

[BMiles]

Correction to Revenue Projection I posted last week -

I previously stated projected revenue from Rh-Apo2L to be $1.2 billion annually, I had mixed up the currency. The annual projection is $150 million the first full year while in production and $225 million the second full year with a projected margin of 40%. Below is a link to a Q & A the company did which discusses this on the third and fourth items from the bottom of page two. This Q & A is a little old as we now know they have completed Pase 2 Clinicle Trials. I think they may also be a little behind schedule as it pertains to production of this drug. The were initialy looking at some point during 2008 but I think projections are now early 2009.

http://www.equityperformancegroup.com/aida_einvestor_kit/QiaerBiotechFAQ.pdf

Q. How much does Aida anticipate generating in revenues from Rh-Apo2L in its first year of commercialization in
2008? How about its second or third year?

A. Aida estimates the revenues of Rh-Apo2L may reach approximately 600 million RMB (US $75 million) in 2008 if the
commercialization is performed as planned and all necessary approvals are received by the SFDA. In 2009 and 2010,
revenues have the potential to reach 1.2 billion RMB (US $150 million) and 1.8 billion RMB (US $225 million)
respectively.


Q. Based on the revenue projections (above), what type of net margins does AIDA anticipate that Rh-Apo2L will
generate?

A. Aida anticipates, if all necessary approvals are received from the SFDA and Rh-Apo2L is brought to market as the plan
outlined above stipulates, net profit margins of Rh-Apo2L could approach 40%.